Robuta

https://tickerspark.ai/market/summit-therapeutics-inc-smmt-drops-9-9-on-profit-taking-1776877577682 Summit Therapeutics Inc. (SMMT) drops 9.9% on profit-taking | TickerSpark Apr 22, 2026 - Summit Therapeutics Inc. (SMMT) drops 9.9% today on profit-taking and no fresh catalyst, as high short interest fuels volatility ahead of ivonescimab updates. summit therapeuticsprofit takingincsmmtdrops https://www.fiercebiotech.com/keyword/summit-therapeutics Summit Therapeutics | Fierce Biotech summit therapeuticsfiercebiotech https://pro.thestreet.com/thefly-newsbreaks/smmt-summit-therapeutics-price-target-raised-by-at-stifel-heres-why Summit Therapeutics price target raised by $6 at Stifel, here's why | TheStreet Pro See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's... summit therapeuticsprice targetraisedstifelthestreet https://de.marketscreener.com/kurs/aktie/SUMMIT-THERAPEUTICS-INC-21452860/news/Transcript-Summit-Therapeutics-Inc-Q1-2024-Earnings-Call-May-01-2024-46594728/ Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 | MarketScreener... summit therapeuticsearnings calltranscriptincmay https://altindex.com/ticker/smmt/twitter-followers Summit Therapeutics (SMMT) X Followers Statistics 2026 Analyze X Followers for Summit Therapeutics and gain a competitive edge with unique and comprehensive information. summit therapeuticsx followerssmmtstatistics https://biohired.com/jobs/98257 IT Business Analyst - G&A at Summit Therapeutics in Palo Alto, CA (US) | Biohired it business analystpalo alto caat summitgtherapeutics https://www.edgen.tech/news/post/summit-therapeutics-stock-drops-25-after-cancer-drug-setback Summit Therapeutics stock drops 25% after cancer drug setback Summit Therapeutics (SMMT) stock fell sharply after an interim analysis of its lead cancer drug, ivonescimab, failed to meet an early endpoint, overshadowing a... summit therapeuticsafter cancerstockdropsdrug https://www.itiger.com/news/2616433901 H.C. Wainwright Sticks to Its Buy Rating for Summit Therapeutics (SMMT) - Tiger Brokers H.C. Wainwright Sticks to Its Buy Rating for Summit Therapeutics (SMMT). On Tiger Brokers' website to stay informed on market trends, price movements, and... summit therapeuticstiger brokerswainwrightsticksbuy https://www.fool.com/investing/2025/07/03/why-summit-therapeutics-stock-soared-8-higher-toda/ Why Summit Therapeutics Stock Soared 8% Higher Today | The Motley Fool Jul 3, 2025 - Why Summit Therapeutics Stock Soared 8% Higher Today the motley foolwhy summittherapeuticsstocksoared https://www.home.saxo/fr-fr/markets/stocks/smmt-xnas Summit Therapeutics Plc action | Saxo Banque Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious... summit therapeuticssaxo banqueplcaction https://ch2report.com/company/cmp__a_ed2qssrngdavkturho Summit Therapeutics Inc. | Chat2Report - Your AI Assistant for Financial Reports | Chat2Report Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal... ai assistant forsummit therapeuticsfinancial reportsinc https://www.panabee.com/news/summit-therapeutics-validates-bispecific-strategy-with-40-risk-reduction-in-head-to-head Summit Therapeutics Validates Bispecific Strategy with 40% Risk Reduction in Head-to-Head Lung... Summit Therapeutics announced strong clinical validation for its lead bispecific antibody, ivonescimab, which demonstrated a 40% reduction in disease... summit therapeuticsrisk reductionbispecificstrategyhead https://pages.m1.com/invest/stocks/SMMT Summit Therapeutics Inc. - SMMT Stock Price Quote & News - M1 Start with SMMT and build your long-term investing strategy with M1. Buy or sell stocks and ETFs commission free. summit therapeuticsstock priceincsmmtquote https://www.bioworld.com/articles/719717-summit-therapeutics-describes-new-kras-g12d-inhibitors-and-degradation-inducers?v=preview Summit Therapeutics describes new KRAS (G12D) inhibitors and degradation inducers | BioWorld Summit Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to a GTPase... summit therapeuticsdescribesnewkrasinhibitors https://public.com/stocks/smmt/pre-market Trade Summit Therapeutics (SMMT) Stock Pre-Market on Public.com Trade Summit Therapeutics (SMMT) stock in the pre-market on Public.com from 4:00 AM to 9:30 AM ET. Track SMMT price, range, and movement before the market... summit therapeuticspre marketpublic comtradesmmt https://www.trade-ideas.com/ticky/ticky.html?symbol=SMMT Summit Therapeutics Inc (SMMT) Stock Analysis Buy and Sell Signals and News | Trade-Ideas buy and sellsummit therapeuticsstock analysistrade ideasinc https://stockti.com/summit-therapeutics-shares-dive-23-after-harmoni-3-update-disappoints Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints | StockTi May 13, 2026 - Summit Therapeutics (SMMT) shares fell 23% after an interim HARMONi-3 trial update for ivonescimab showed no early benefit. Final PFS data expected in summit therapeuticssharesdiveharmoniupdate https://pharma.economictimes.indiatimes.com/news/pharma-industry/astrazeneca-and-summit-therapeutics-explore-15-billion-cancer-drug-deal/122238601 AstraZeneca Cancer Drug Licensing Deal: AstraZeneca and Summit Therapeutics Explore $15 Billion... AstraZeneca Cancer Drug Licensing Deal: AstraZeneca is negotiating with Summit Therapeutics for a potential licensing agreement valued at $15 billion for the... summit therapeuticsastrazenecacancerdruglicensing https://carb-x.org/carb-x-news/summit-therapeutics-nominates-carb-x-funded-smt-571-as-lead-clinical-candidate-for-treatment-of-gonorrhoea/ Summit Therapeutics nominates CARB-X-funded SMT-571 as lead clinical candidate for treatment of... summit therapeuticscarbxfundedsmt https://www.biotechtv.com/all-videos/tags/summit-therapeutics Summit Therapeutics | BiotechTV summit therapeutics https://www.hl.co.uk/shares/shares-search-results/s/summit-therapeutics-inc-usd0.01 Summit Therapeutics Inc USD0.01 share price | SMMT The latest Summit Therapeutics Inc USD0.01 share price (SMMT). View recent trades and share price information for Summit Therapeutics Inc USD0.01. summit therapeuticsshare priceincsmmt https://www.resumemate.io/jobs/account-director-remote-jobs/7e7a1e_summittherapeutics_4195442009 Corporate Account Director, GPO at Summit Therapeutics | ResumeMate Apply for Corporate Account Director, GPO at Summit Therapeutics in Remote (US). Skills: GPO, Market Access, Oncology Reimbursement. Apply now on ResumeMate. corporate accountsummit therapeuticsdirectorgpo https://himsstv.brightcovegallery.com/detail/videos/digital-therapeutics-alliance-summit-2024/video/6354711379112/dta-directtrust-highlights-newly-formed-partnership?autoStart=true DTA, DirectTrust highlights newly formed partnership - Digital Therapeutics Alliance Summit 2024 -... Scott Stuewe, president and CEO of DirectTrust, and Andy Molnar, CEO of the Digital Therapeutics Alliance, highlight the partners' efforts to move digital... digital therapeuticsalliance summitdtahighlightsnewly